KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Equity Ratio (2017 - 2026)

Amneal Pharmaceuticals has reported Equity Ratio over the past 9 years, most recently at 0.02 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 38.0% year-over-year to 0.02; the TTM value through Dec 2025 reached 0.02, up 38.0%, while the annual FY2025 figure was 0.02, 38.0% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.02 at Amneal Pharmaceuticals, up from 0.03 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.1 in Q1 2022 and troughed at 0.04 in Q1 2025.
  • A 5-year average of 0.03 and a median of 0.04 in 2023 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: plummeted 642.75% in 2024 and later soared 38.0% in 2025.
  • Year by year, Equity Ratio stood at 0.09 in 2021, then tumbled by 48.01% to 0.05 in 2022, then tumbled by 88.1% to 0.01 in 2023, then plummeted by 642.75% to 0.03 in 2024, then skyrocketed by 38.0% to 0.02 in 2025.
  • Business Quant data shows Equity Ratio for AMRX at 0.02 in Q4 2025, 0.03 in Q3 2025, and 0.03 in Q2 2025.